Ofcrom-OR Oral Suspension is a combination pharmaceutical formulation containing Ofloxacin (50mg/5ml), Ornidazole (125mg/5ml), and Racecadotril (10mg/5ml), designed for the treatment of mixed bacterial and protozoal infections accompanied by acute diarrhea. Ofloxacin, a fluoroquinolone antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, effectively targeting a wide range of Gram-positive and Gram-negative pathogens. Ornidazole, a nitroimidazole derivative, provides potent antiprotozoal and antibacterial effects, particularly against anaerobic organisms and protozoa such as Giardia lamblia and Entamoeba histolytica. Racecadotril, an enkephalinase inhibitor, acts as an antisecretory agent by reducing intestinal hypersecretion of water and electrolytes, thereby alleviating symptoms of acute diarrhea without affecting intestinal motility. The combined action of these agents makes Ofcrom-OR Oral Suspension suitable for managing infections where mixed aerobic and anaerobic bacteria coexist with protozoal pathogens, often presenting with diarrheal symptoms. This formulation is typically prescribed for gastrointestinal infections including bacterial dysentery, amoebiasis, and traveler’s diarrhea. Administration should follow medical guidance, considering patient-specific factors such as age, renal function, and potential drug interactions. Caution is advised in patients with hypersensitivity to fluoroquinolones, nitroimidazoles, or racecadotril.